{
    "2021-07-14": [
        [
            {
                "time": "",
                "original_text": "西部证券：给予泰格医药买入评级，目标价位223.2元",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "买入评级",
                        "目标价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "西部证券给予泰格医药买入评级，首次覆盖报告：中国临床CRO龙头，国际业务布局加速，目标价223.2元",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "买入评级",
                        "CRO",
                        "国际业务",
                        "龙头"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "泰格医药发起设立的生物医药产业基金落地杭州，总规模200亿",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "生物医药产业基金",
                        "杭州",
                        "规模200亿"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：医药板块估值已具备吸引力 建议长期配置优质赛道",
                "features": {
                    "keywords": [
                        "医药生物",
                        "估值",
                        "吸引力",
                        "长期配置",
                        "优质赛道"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：短期受政策扰动 关注中报高成长个股",
                "features": {
                    "keywords": [
                        "医药生物",
                        "政策扰动",
                        "中报",
                        "高成长个股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "CXO板块逆势走强，康龙化成涨超5%再创新高",
                "features": {
                    "keywords": [
                        "CXO",
                        "逆势走强",
                        "康龙化成",
                        "涨超5%",
                        "新高"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "CXO"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "领跌CRO淘金赛道：泰格医药转型“投资家”AB面 非经常性损益突出",
                "features": {
                    "keywords": [
                        "CRO",
                        "泰格医药",
                        "转型",
                        "投资家",
                        "非经常性损益"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}